Replies to post #220 on Cardiol Therapeutics Inc (CRDL)

[tw0122]

Chart looking good $2.07 next targets $4

[MahinAgency]

NASDAQ: $CRDL
ARCHER trial completed enrollment, with results expected in Q1 2025. Orphan status could lead to $120M peak sales 

Promising early results, potential approval by 2027, targeting $609M peak sales

[MahinAgency]

Breaking News: NASDAQ: $CRDL unveils groundbreaking results for CardiolRx™ at the American Heart Association Conference! 📷 Rapid pain relief, 85% fewer recurrences, and lasting inflammation reduction.

[MahinAgency]

INSIDER BUYING : Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.